Literature DB >> 14768774

The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: evidence supporting central obesity.

B Susleyici Duman1, C Turkoglu, D Gunay, P Cagatay, C Demiroglu, A Sevim Buyukdevrim.   

Abstract

This paper investigates the relative role of the impairment of insulin secretion and action in the pathogenesis of Type 2 diabetes mellitus (T2DM). The parameters indicating insulin secretion and action were calculated from the data obtained during oral glucose tolerance test (OGTT), in 156 age- and sex-matched T2DM patients divided in 4 groups according to their body mass index (BMI, I = 20.0-24.9, II = 25.0-29.9, III = 30.0-39.9 and IV > 40.0 kg/m2). After obtaining baseline biomedical parameters (plasma glucose, serum insulin, cholesterol, HDL-cholesterol, triglycerides, BMI, and amount of fat tissue), the rates of insulin secretory capacity and insulin action were obtained from OGTT and compared between the T2DM patients with normal body weight and different grades of obesity. Beta-cell secretory capacity of the participants was found to be proportionally and significantly higher in graded obese than that of the normal body weight patients. The rates of hepatic as well as peripheral insulin resistance in obese groups proportionally and significantly rise in comparison with that of non-obese diabetics. In addition, these parameters are shown to be related to the body fat, presumably visceral in origin. In conclusion, hyperglycemia-hyperinsulinemia observed in obese and T2DM patients might be due, in part, to increased capacity of insulin secretion, and to exaggerated hepatic glucose production because of hepatic insulin resistance, respectively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14768774

Source DB:  PubMed          Journal:  Diabetes Nutr Metab        ISSN: 0394-3402


  6 in total

1.  Shox2 is a molecular determinant of depot-specific adipocyte function.

Authors:  Kevin Y Lee; Yuji Yamamoto; Jeremie Boucher; Jonathon N Winnay; Stephane Gesta; John Cobb; Matthias Blüher; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

2.  Effect of obesity and insulin resistance on diabetic control.

Authors:  Kumud Kale; D K Rawat
Journal:  Indian J Clin Biochem       Date:  2006-03

3.  Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis.

Authors:  Simona Di Francesco; Raffaele L Tenaglia
Journal:  Cent European J Urol       Date:  2014-01-27

4.  Structured lifestyle intervention based on a trans-cultural diabetes-specific nutrition algorithm (tDNA) in individuals with type 2 diabetes: a randomized controlled trial.

Authors:  Winnie S S Chee; Harvinder Kaur Gilcharan Singh; Osama Hamdy; Jeffrey I Mechanick; Verna K M Lee; Ankur Barua; Siti Zubaidah Mohd Ali; Zanariah Hussein
Journal:  BMJ Open Diabetes Res Care       Date:  2017-09-26

5.  Lixisenatide as add-on treatment among patients with different β-cell function levels as assessed by HOMA-β index.

Authors:  Riccardo C Bonadonna; Lawrence Blonde; Mikhail Antsiferov; Rachele Berria; Pierre Gourdy; Mensud Hatunic; Viswanathan Mohan; Michael Horowitz
Journal:  Diabetes Metab Res Rev       Date:  2017-06-20       Impact factor: 4.876

6.  Comparing the accuracy of ES-BC, EIS-GS, and ES Oxi on body composition, autonomic nervous system activity, and cardiac output to standardized assessments.

Authors:  John E Lewis; Stacey L Tannenbaum; Jinrun Gao; Angelica B Melillo; Evan G Long; Yaima Alonso; Janet Konefal; Judi M Woolger; Susanna Leonard; Prabjot K Singh; Lawrence Chen; Eduard Tiozzo
Journal:  Med Devices (Auckl)       Date:  2011-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.